Novartis’ Oral MS Drug Strong In Three-year Phase II Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Side effects rang alarms early on, but disappeared over time.
You may also be interested in...
Serono Taps Aussie Biotech For New MS Drugs
Licensing deal includes up to $47 million per developed drug and full research funding.
Serono Taps Aussie Biotech For New MS Drugs
Licensing deal includes up to $47 million per developed drug and full research funding.
Infections, Death Fail To Stop Novartis’ Phase III MS Trial
“Confounding” factors in play; monitoring board gives green light to continue.